AstraZeneca is reviewing its UK financial PR business amid media speculation on a possible acquisitions run in the US, reports our sister publication, PRWeek UK.
The company is hearing pitches from multiple city of London communications agencies including incumbent Brunswick, FD, Finsbury and Tulchan Communications, all of which specialize in financial PR. The business is worth a sum in the low six figures in fees, though project work around mergers and acquisitions could pad that out considerably, reported PRWeek UK. The review comes amid speculation that the company could buy Shire and beef up its US operations through acquisitions.